Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
McKesson
McKinsey
Mallinckrodt
AstraZeneca

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for Mavoglurant


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Mavoglurant?

Mavoglurant is an investigational drug.

There have been 5 clinical trials for Mavoglurant. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2013.

The most common disease conditions in clinical trials are Alcoholism, Compulsive Personality Disorder, and Alcohol Drinking. The leading clinical trial sponsors are Novartis Pharmaceuticals, Yale University, and National Institute of Neurological Disorders and Stroke (NINDS).

There are sixty-two US patents protecting this investigational drug and six hundred and ninety-one international patents.

Recent Clinical Trials for Mavoglurant
TitleSponsorPhase
Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHNYale UniversityEarly Phase 1
Mavoglurant in Alcohol DrinkingYale UniversityPhase 1
Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)Novartis PharmaceuticalsPhase 2

See all Mavoglurant clinical trials

Clinical Trial Summary for Mavoglurant

Top disease conditions for Mavoglurant
Top clinical trial sponsors for Mavoglurant

See all Mavoglurant clinical trials

US Patents for Mavoglurant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Mavoglurant ⤷  Try it Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Try it Free
Mavoglurant ⤷  Try it Free Methods of treating sleep disorders Melior Pharmaceuticals II, LLC (Exton, PA) ⤷  Try it Free
Mavoglurant ⤷  Try it Free Composition and method for treating neurological disease Osmotica Kereskedelmi es Szolgaltato Korlatolt Feleossegu Tarsasag (Budapest, HU) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
McKesson
McKinsey
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.